Alveus Therapeutics Secures $160M Series A for Obesity, Metabolic Disease Innovation
January 13, 2026, 9:32 pm
Location: United States, Massachusetts, Cambridge
Employees: 10001+
Founded date: 1981
Total raised: $1.1B
Alveus Therapeutics, a Philadelphia-based biotech company, raised $160M in Series A funding. This significant capital infusion targets advanced therapies for obesity and metabolic diseases. New Rhein, Andera Partners, and Omega Funds led the round. Sanofi Capital and others also participated. The funds will propel R&D, notably supporting Phase 2 clinical development of ALV-100, a promising bifunctional fusion protein. This therapy combines GIP receptor antagonism with GLP-1 receptor agonism for sustained weight loss. The company also advances other innovative candidates. New board appointments strengthen governance. Alveus aims for superior, durable treatment outcomes, addressing a critical global health challenge. This move positions Alveus as a leader in next-generation metabolic disease solutions.
Alveus Therapeutics now commands substantial capital. A $160 million Series A funding round concluded. This significant infusion fuels groundbreaking work. The clinical-stage biotechnology company targets a critical global health challenge. Its focus: obesity and metabolic diseases. These conditions affect hundreds of millions worldwide. They represent a significant burden on healthcare systems.
A powerful consortium of investors spearheaded the financing. New Rhein Healthcare Investors led the charge. Andera Partners and Omega Funds co-led the round. Esteemed healthcare investors joined this syndicate. Sanofi Capital, Kurma Partners, and Avego BioScience Capital participated. This broad participation signals strong market confidence. It validates Alveus's innovative approach.
The newly secured funds target aggressive expansion. Research and development efforts will accelerate dramatically. Alveus seeks to deliver sustained therapeutic efficacy. Improved tolerability is a key design principle. Reduced treatment burden remains a core goal. These advancements are crucial for patient adherence and quality of life. Raj Kannan leads Alveus as its Chief Executive Officer. His strategic vision guides the company's trajectory.
Alveus's operational footprint is global. Its headquarters are established in Philadelphia, Pennsylvania. Research and development activities thrive in Copenhagen, Denmark. This transatlantic presence ensures broad scientific collaboration. It also facilitates efficient clinical operations. Global reach defines Alveus's strategy for innovation.
ALV-100 stands as Alveus's flagship program. This lead candidate will advance into Phase 2 clinical development. ALV-100 represents a novel therapeutic mechanism. It is a bifunctional fusion protein. This innovative design combines two potent pathways. GIP receptor antagonism is one component. GLP-1 receptor agonism forms the other. This dual action promises robust and potent weight loss. The therapy aims for sustained efficacy, a significant unmet need. Long-term weight maintenance is a critical outcome. Many existing treatments struggle with this aspect. ALV-100 directly addresses this persistent challenge. It seeks to redefine standards for obesity management.
Alveus's pipeline extends beyond ALV-100. The company actively develops other proprietary candidates. Plans are underway for multiple Investigational New Drug (IND) filings. One promising candidate is a highly selective Amylin peptide agonist. Early-stage development also features ALV-200. This is a highly selective amylin receptor 3 (AMYR3) peptide agonist. Furthermore, Alveus explores amylin-based small-molecule oral candidates. Multifunctional biologic formats are also under active development. This diverse portfolio underscores a comprehensive strategy. Alveus pursues multiple therapeutic avenues against metabolic disorders.
The global epidemic of obesity continues to escalate. Existing therapeutic options often provide insufficient long-term solutions. Patients frequently struggle with maintaining initial weight loss. This reality creates an urgent demand for advanced treatments. Alveus seeks to disrupt this landscape. Its next-generation therapies aim for durable efficacy. Infrequent dosing regimens are a significant design goal. Improved tolerability is central to patient acceptance. Better body-composition outcomes are also expected. The overarching goal is transformative patient care. Alveus aims for meaningful, lasting health improvements.
Strategic leadership receives a significant boost. Jan Van den Bossche joins the Alveus Board of Directors. He brings expertise from Andera Partners. Claudio Nessi also joins the board. He serves as a Managing Director at Omega Funds. Their collective experience bolsters corporate governance. These additions provide invaluable guidance. They will help shape Alveus's strategic direction. The board gains deep, critical industry insight.
The Alveus team possesses profound experience. Its members hold a proven track record. They have successfully guided metabolic medicines. These innovations moved from early concept to commercialization. This accumulated expertise is invaluable. The company is exceptionally well-positioned. It can truly lead the next wave of innovation. Obesity therapeutics are rapidly evolving. Alveus strives to be at the forefront of this evolution.
This significant investment underscores strong confidence. It affirms Alveus's immense potential. Setting new standards of care appears within reach. The company's mission aligns with true innovation. It seeks to make a lasting difference in patients’ lives. Preclinical and clinical operations are robust. They efficiently span both the US and Denmark. This dual presence ensures global reach. It guarantees executional excellence.
Alveus combines expansive global reach. It pairs this with strong executional capabilities. The team demonstrates clear ambition. It seeks a meaningful impact on global health. Innovation will scale worldwide. The $160 million empowers this grand vision. It accelerates vital drug discovery processes. It speeds development toward patients in need. This capital injection marks a pivotal moment. The entire biotech sector watches closely. Alveus Therapeutics moves forward decisively. It stands poised to revolutionize metabolic health.
Alveus Therapeutics now commands substantial capital. A $160 million Series A funding round concluded. This significant infusion fuels groundbreaking work. The clinical-stage biotechnology company targets a critical global health challenge. Its focus: obesity and metabolic diseases. These conditions affect hundreds of millions worldwide. They represent a significant burden on healthcare systems.
A powerful consortium of investors spearheaded the financing. New Rhein Healthcare Investors led the charge. Andera Partners and Omega Funds co-led the round. Esteemed healthcare investors joined this syndicate. Sanofi Capital, Kurma Partners, and Avego BioScience Capital participated. This broad participation signals strong market confidence. It validates Alveus's innovative approach.
The newly secured funds target aggressive expansion. Research and development efforts will accelerate dramatically. Alveus seeks to deliver sustained therapeutic efficacy. Improved tolerability is a key design principle. Reduced treatment burden remains a core goal. These advancements are crucial for patient adherence and quality of life. Raj Kannan leads Alveus as its Chief Executive Officer. His strategic vision guides the company's trajectory.
Alveus's operational footprint is global. Its headquarters are established in Philadelphia, Pennsylvania. Research and development activities thrive in Copenhagen, Denmark. This transatlantic presence ensures broad scientific collaboration. It also facilitates efficient clinical operations. Global reach defines Alveus's strategy for innovation.
ALV-100 stands as Alveus's flagship program. This lead candidate will advance into Phase 2 clinical development. ALV-100 represents a novel therapeutic mechanism. It is a bifunctional fusion protein. This innovative design combines two potent pathways. GIP receptor antagonism is one component. GLP-1 receptor agonism forms the other. This dual action promises robust and potent weight loss. The therapy aims for sustained efficacy, a significant unmet need. Long-term weight maintenance is a critical outcome. Many existing treatments struggle with this aspect. ALV-100 directly addresses this persistent challenge. It seeks to redefine standards for obesity management.
Alveus's pipeline extends beyond ALV-100. The company actively develops other proprietary candidates. Plans are underway for multiple Investigational New Drug (IND) filings. One promising candidate is a highly selective Amylin peptide agonist. Early-stage development also features ALV-200. This is a highly selective amylin receptor 3 (AMYR3) peptide agonist. Furthermore, Alveus explores amylin-based small-molecule oral candidates. Multifunctional biologic formats are also under active development. This diverse portfolio underscores a comprehensive strategy. Alveus pursues multiple therapeutic avenues against metabolic disorders.
The global epidemic of obesity continues to escalate. Existing therapeutic options often provide insufficient long-term solutions. Patients frequently struggle with maintaining initial weight loss. This reality creates an urgent demand for advanced treatments. Alveus seeks to disrupt this landscape. Its next-generation therapies aim for durable efficacy. Infrequent dosing regimens are a significant design goal. Improved tolerability is central to patient acceptance. Better body-composition outcomes are also expected. The overarching goal is transformative patient care. Alveus aims for meaningful, lasting health improvements.
Strategic leadership receives a significant boost. Jan Van den Bossche joins the Alveus Board of Directors. He brings expertise from Andera Partners. Claudio Nessi also joins the board. He serves as a Managing Director at Omega Funds. Their collective experience bolsters corporate governance. These additions provide invaluable guidance. They will help shape Alveus's strategic direction. The board gains deep, critical industry insight.
The Alveus team possesses profound experience. Its members hold a proven track record. They have successfully guided metabolic medicines. These innovations moved from early concept to commercialization. This accumulated expertise is invaluable. The company is exceptionally well-positioned. It can truly lead the next wave of innovation. Obesity therapeutics are rapidly evolving. Alveus strives to be at the forefront of this evolution.
This significant investment underscores strong confidence. It affirms Alveus's immense potential. Setting new standards of care appears within reach. The company's mission aligns with true innovation. It seeks to make a lasting difference in patients’ lives. Preclinical and clinical operations are robust. They efficiently span both the US and Denmark. This dual presence ensures global reach. It guarantees executional excellence.
Alveus combines expansive global reach. It pairs this with strong executional capabilities. The team demonstrates clear ambition. It seeks a meaningful impact on global health. Innovation will scale worldwide. The $160 million empowers this grand vision. It accelerates vital drug discovery processes. It speeds development toward patients in need. This capital injection marks a pivotal moment. The entire biotech sector watches closely. Alveus Therapeutics moves forward decisively. It stands poised to revolutionize metabolic health.